knowledge -WSS

knowledge

author：comprehensive 2025-09-29 01:37:41 - browse：2

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Data show record exodus of life scientists from academia

WSS

After a drawn out lobbying fight, ARPA

FDA poised to publish guidelines for clinical trial diversity

FDA advisers vote against ALS treatment from BrainStorm

Bird flu surveillance in wastewater gets boost from consortium

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Liver decline slowed by off

hotspot

knowledge

leisure time

Walensky prepares to leave CDC — and Congress — behind

Study finds gene variants tied to breast cancer risk in Black women

In age of alternative facts, a scholarly course on calling out crap

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Heart attack and stroke risk calculators need revising

FDA poised to publish guidelines for clinical trial diversity

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Menendez indictment could see pharma lose a key ally

Apple is now the first public company to be valued at $3 trillion

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

knowledge

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Paxlovid should be available without a positive Covid test

How one patient went off dialysis — and others can too

FDA seeks to regulate lab

Researchers use wearables data and AI to predict preterm birth risk

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

hotspot

hotspot

explore

knowledge